https://www.selleckchem.com/pr....oducts/i-bet151-gsk1
Data on the long-term administration of ustekinumab in recommended doses are limited. To assess the real-world, long-term effectiveness of ustekinumab in refractory Crohn's disease (CD). Multi-centre study of CD patients starting ustekinumab at the recommended dose, followed for 1year. Values for the Harvey-Bradshaw Index (HBI), endoscopic activity, C-reactive protein (CRP), and faecal calprotectin (FC) were recorded at baseline and at weeks 26 and 52. Demographic and clinical data, previous treatments, adverse events (AEs)
Curtir
Comentario
Compartilhar
